PDCD1 and melanoma: Among various immunotherapeutic modalities, immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 and CTLA-4 have achieved unprecedented success in tumors such as melanoma, non-small cell lung cancer, and renal cell carcinoma [1–4].